TOG Review (RCOG Journal)
MRCOG Part 2
Maternal Medicine
Sarcoidosis in pregnancy
Key Statistics
- 1:2000–1:10,464 — Prevalence in pregnancy
- OR 1.62 — Pre-eclampsia risk (Hadid)
- OR 6.68 — Pulmonary embolus risk (Hadid)
Don't-miss facts
-
Sarcoidosis in pregnancy: multisystem, non-caseating granulomas; pulmonary artery hypertension and severe ILD (FVC <1–1.5 L) are high maternal mortality risks – MDT pre-pregnancy discussion essential
-
Cardiac sarcoidosis (up to 39%): syncope may be first sign; arrhythmia risk 2–7%; ICDs safe in pregnancy but need interrogation ± deactivation in labour
-
Postnatal flare is common – 25/38 new diagnoses in the Selroos cohort occurred within 1 year of delivery; plan postnatal flare suppression
-
Serum ACE is unreliable for monitoring in pregnancy
-
Aspirin from 12 weeks; avoid calcium/vitamin D supplementation (abnormal calcium metabolism)
-
Methotrexate and MMF contraindicated in pregnancy/breastfeeding; methotrexate stop 4 weeks pre-conception (+folate 5 mg/day to 12 weeks if late stop); MMF stop ≥6 weeks pre-conception
-
Sarcoidosis alone is not an indication for caesarean section, but consider cardiorespiratory reserve and shortened second stage
-
Hadid registry: ↑PE (OR 6.68), ↑DVT (OR 4.92), ↑pre-eclampsia (OR 1.62); Köcher registry: ↑emergency CS, ↑pre- eclampsia (RR 1.6), no ↑VTE
Drug safety at a glance
Safe: corticosteroids, azathioprine, anti-TNF biologics (with timing caveats) Avoid: methotrexate, MMF, leflunomide
Abbreviation Key
- TH1/TH2 — T helper 1 / T helper 2 lymphocyte response
- EMG — electromyography
- Treg — regulatory T cell
- ICD — implantable cardiac defibrillator
- TNF-α — tumour necrosis factor alpha
- MMF — mycophenolate mofetil
- ILD — interstitial lung disease
- Anti-TNF — anti-tumour necrosis factor biologic therapy
- FVC — forced vital capacity
- IUD — intra-uterine death
- ACE — angiotensin converting enzyme
- PPH — postpartum haemorrhage
- CT — computerised tomography
- VTE — venous thromboembolism
- MRI — magnetic resonance imaging
- OR/RR — odds ratio / relative risk
Source: Odendaal J et al. Sarcoidosis in pregnancy. The Obstetrician & Gynaecologist 2024;26:66–74. doi:10.1111/tog.12917
MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).